Executive Summary
A thin clinical news day is dominated by computational and procedural mechanics rather than fresh outcomes — a finite-element simulation in Computer Methods and Programs in Biomedicine shows leaflet resection during redo-TAVI improves second-valve expansion by ~30% and cuts mean gradient by 21-38%, sharpening the engineering case for dedicated leaflet-removal tools as the redo-TAVI cohort grows. Separately, a Journal of Biomechanics computational study begins to mechanistically explain the annuloplasty effect observed after tricuspid TEER, quantifying TriClip-induced annular forces averaging 2.00±1.68 N and SL diameter reductions of ~2%. CMS opened public comments on the TAVR National Coverage Analysis (CAG-00430R2), the first formal reopening since the 2019 NCD — which loosens the coverage envelope at exactly the moment ESC 2025 dropped the TAVI-preferred threshold to age 70.
- Leaflet resection in simulated redo-TAVI improves EOA 11-24% and reduces eccentricity >80% in size-mismatched configurations — engineering signal for next-gen resection tools (Comput Methods Programs Biomed).
- Tricuspid TEER's annuloplasty effect quantified: XTW clips generate more annular force and leaflet stress than NTW; central anterior-posterior placement maximizes force transmission (J Biomech).
- CMS reopens TAVR National Coverage Analysis — first formal review since 2019, with public comments now posted (CMS).
- A Canadian Journal of Cardiology editorial revisits post-TAVR pacing strategy with a focus on preserving ventricular function — a chronic blind spot in TAVI durability discussions (Can J Cardiol).
- Edwards holds near 6-month highs ($90.78) on positive New York Valves trial readouts ahead of July 23 earnings; Boston Scientific trades near 52-week lows (simplywall.st).
What to watch: Edwards earnings July 23 — first read on Evoque and PASCAL pull-through after the ESC 2025 tricuspid IIa upgrade and the still-open CMS TAVR coverage review.
Aortic Valve (TAVR/TAVI)
Today's aortic story is about engineering the second valve, not the first. A patient-specific finite-element / SPH model from Scuoppo and colleagues shows that performing complete leaflet resection before redo-TAVI improves expansion of the second device by approximately 30% at the annulus, drops eccentricity by up to 80% in size-mismatched scenarios, and raises EOA 11-24% with mean gradient reductions of 21-38% across both Sapien 3 and Evolut PRO configurations. This is computational, single-anatomy, no clinical endpoints — but it directly informs why BASILICA, ShortCut, and emerging dedicated leaflet-resection systems matter: residual fixed leaflets from the index valve are mechanically constraining the redo device, not just risking coronary obstruction. ACC/AHA 2020 and ESC 2025 both emphasize lifetime management at the index TAVI as paramount when life expectancy exceeds assumed durability, with TAV-in-TAV PPM risk and coronary access among the chief concerns. Surgical counterpoint: redo-SAVR remains the gold standard durability comparator and avoids these residual-leaflet mechanics entirely; ESC 2025 explicitly notes THV explantation carries 12-17% mortality, which is the relevant denominator for any redo strategy. Separately, a Canadian Journal of Cardiology piece reopens the pacing-after-TAVR question with an explicit focus on preserving ventricular function — long overdue given that the conduction-disturbance literature (including the recent SAVR comparison data on BAV-AS) shows new LBBB independently raises mortality.
Mitral Valve (MitraClip, PASCAL, TMVR)
No registry, RCT, or guideline-relevant mitral data today. The lone mitral item is local: Pikeville Medical Center completed its first solo MitraClip, a marker of continued community-hospital diffusion of TEER. The relevant clinical context: ESC 2025 elevated M-TEER for ventricular secondary MR to Class I (LOE A) based on COAPT 5-year data plus RESHAPE-HF2's 36% reduction in HF hospitalization/CV death; ACC/AHA 2020 still rates it Class IIa. Diffusion to non-referral centers is the natural consequence of a Class I European indication and a Class IIa US one, but the COAPT eligibility envelope (LVEF 20-50%, LVESD ≤70mm, SPAP ≤70mmHg, GDMT-optimized, no severe RV dysfunction) is narrow enough that case selection at community sites bears scrutiny. The surgical comparator hasn't moved: durable mitral repair at experienced centers remains Class I for primary MR, and ESC 2025 broadened the asymptomatic primary-MR repair indication to Class I when three of AF, SPAP >50, LA dilation, or ≥moderate TR coexist. TEER is not a substitute for repair in degenerative disease.
Tricuspid Valve (TriClip, TTVR)
The mechanism behind tricuspid TEER's "annuloplasty effect" gets a first quantitative answer. In 34 simulated TriClip deployments across three human tricuspid valve finite-element models, Haese and colleagues measured TEER-induced annular forces of 2.00 ± 1.68 N, correlated with annular area reduction of 3.11 ± 2.29% and SL diameter reduction of 2.10 ± 2.25% (both p<0.0001). Larger XTW clips generated more annular force and more leaflet stress than NTW; central anterior-posterior placement transmitted more force than near-annulus placement. Caveats are inline: three valves, computational, no clinical outcomes, no chronic remodeling — but the finding clarifies why TRILUMINATE Pivotal and Tri.Fr show progressive geometric improvement beyond the leaflet itself, and gives operators a mechanistic rationale for clip choice and placement that has been largely empirical to date. ESC 2025 made transcatheter tricuspid therapy Class IIa (LOE A) on the strength of TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II; ACC/AHA 2020 has no recommendation because the trials hadn't read out. Surgical counterpoint: isolated tricuspid surgery historically carried 8-20% mortality with late referral, and ESC 2025 upgraded symptomatic primary TR to Class I surgical and asymptomatic primary TR with RV dilation to Class IIa. The 30-day TTVR mortality of 3.1% in the STS/ACC TVT Registry EVOQUE cohort is the number that anchors the new transcatheter case. Also today: an IJC corrigendum on the K-Clip first-in-human study — a reminder that the annular-cinching device class is alive in China and an outlier worth tracking against leaflet-approximation devices.
Regulatory & Policy
CMS opened public comments on TAVR NCD reconsideration CAG-00430R2. The current NCD dates to 2019 and codifies the two-cardiac-surgeon assessment plus minimum volume thresholds — both controversial as TAVI has moved into low-risk, lower-volume centers. A reconsideration opens the door to revising volume floors, the surgeon-assessment requirement, or asymptomatic-AS coverage following EARLY TAVR. The timing matters: ESC 2025 already dropped the TAVI-preferred age threshold to 70 (with SAVR preferred only <70 at low surgical risk), and EARLY TAVR has made early intervention in asymptomatic severe AS a Class IIa ESC recommendation. If CMS follows the European drift, the US TAVI envelope expands materially. The surgical community — Badhwar, Mehaffey, Chikwe among others — has been explicit that volume requirements and surgeon assessment exist to protect patients in a field moving faster than its durability evidence. Watch the comment file.
Other Cardiac Procedures
Two adjacent but valve-relevant reviews landed in JCVA. The first frames VA-ECMO use during high-risk VT ablation: Munoz-Acuna and colleagues conclude VA-ECMO is appropriate only for biventricular dysfunction, electrical storm, cardiogenic shock, or profound VT intolerance — Impella or IABP suffice in isolated LV dysfunction. No survival benefit demonstrated; this is procedural feasibility data only. Second, a review of complex PFO closure addresses long tunnels, atrial septal aneurysms, multifenestrated septa, and prominent Eustachian valves — the structural-heart cases that get harder as PFO closure has become routine. Both are pertinent because the structural-heart team increasingly owns the full intracardiac portfolio, and selection failure in either domain spills into valve operator credibility.
Industry & Market
Edwards is being repriced around the New York Valves meeting. Simplywall.st and AD HOC News both frame EW as undervalued given the trial readouts feeding the July 23 print. Boston Scientific's commentary is the inverse: strategy-focus coverage and cautious consensus notes note BSX shares near 1-year lows even as WATCHMAN FLX Pro rolls out. The clinical context behind the EW strength: Evoque coming off the TRISCEND II Class IIa ESC tailwind, SAPIEN 3 still the volume base, EARLY TAVR pulling forward asymptomatic-AS volume. The clinical context for BSX softness: WATCHMAN is left-atrial appendage, not valve — the valve portfolio (ACURATE neo2 in Europe) hasn't moved the US needle.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $90.78 (+1.18% on the day); 6-month change +4.42%; 52-week range $72.30–$92.46 — trading at the top of the range.
- Market Cap: $52.3B | P/E trailing: 49.07 | P/E forward: 26.96 | Beta: 0.87
- Analyst consensus: Buy; mean target $96.92 (range $84-$110, 26 analysts) — ~7% implied upside.
- Next earnings: July 23 (EPS est $0.74, Rev est $1.70B).
- Commentary: The New York Valves data and Evoque ramp behind a Class IIa ESC tricuspid endorsement give Edwards the cleanest narrative in the group. PASCAL remains a distant #2 to MitraClip but ESC's Class I M-TEER ventricular-SMR upgrade lifts the whole category. The stock's main vulnerability is the TAVI durability question at 10 years — every PARTNER 3 / Evolut LR readout matters.
Medtronic (MDT)
- Close: $80.98 (+1.48% on the day); 6-month range $72.65–$103.71 — well off highs.
- Market Cap: $103.7B | P/E trailing: 21.71 | P/E forward: 12.64 | Beta: 0.60
- Analyst consensus: Buy; mean target $98.00 (range $78-$121, 26 analysts) — ~21% implied upside.
- Next earnings: August 18 (EPS est $1.39, Rev est $9.55B).
- Commentary: Evolut LR's 5-year and longer data anchor the durability case for self-expanding TAVI, and the DEDICATE readout reinforces TAVI non-inferiority in low-risk patients. The stock's discount reflects portfolio breadth concerns rather than valve-specific issues. ESC 2025's age-70 TAVI threshold is materially supportive to the franchise.
Abbott (ABT)
- Close: $94.12 (+0.94% on the day); 6-month change -23.58%; 52-week range $81.97–$137.49.
- Market Cap: $163.9B | P/E trailing: 26.36 | P/E forward: 15.54 | Beta: 0.62
- Analyst consensus: Buy; mean target $116.54 (range $92-$135, 24 analysts) — ~24% implied upside.
- Next earnings: July 16 (EPS est $1.28, Rev est $12.53B).
- Commentary: Abbott carries the MitraClip franchise plus TriClip (NTW/XTW) and Navitor TAVI. Today's tricuspid-TEER mechanism paper directly validates the TriClip design hypothesis — larger XTW clips drive more annular force. The 6-month underperformance is diagnostics/lawsuit overhang, not structural-heart fundamentals; the valve portfolio remains a category leader.
Boston Scientific (BSX)
- Close: $44.23 (+0.07% on the day); 6-month change -53.81%; trading at the 52-week low ($43.89).
- Market Cap: $65.7B | P/E trailing: 18.51 | P/E forward: 11.89 | Beta: 0.56
- Analyst consensus: Buy; mean target $75.00 (range $55-$106, 29 analysts) — ~70% implied upside.
- Next earnings: July 29 (EPS est $0.83, Rev est $5.37B).
- Commentary: The 54% drawdown is the steepest in the group and out of step with the underlying business — WATCHMAN FLX Pro is rolling, ACURATE neo2 is the European TAVI alternative, and EP/CRM is robust. The valve franchise is the smallest of the four majors, which makes BSX least exposed to the TAVI durability debate but also least levered to ESC 2025's age-70 shift.
Anteris Technologies (AVR.AX)
- Close: AUD $13.59 (-4.77% on the day); 6-month change +74.23%; near 52-week high.
- Market Cap: AUD $1.3B | Forward P/E: -6.23 (pre-revenue) | Beta: 0.73
- Analyst coverage: Thin (1 analyst, target AUD $13.00).
- Commentary: DurAVR single-piece bovine pericardial THV remains the differentiated bet against the four-leaflet/three-leaflet incumbents; the 74% 6-month run reflects pivotal-trial enrollment momentum. Speculative — no Phase III readout, no commercial revenue, no peer to anchor valuation.
Market outlook: The valve-stock signal this quarter is bifurcated. EW and ABT — the structural-heart-pure plays — sit at or near 52-week highs heading into July earnings, propelled by the ESC 2025 expansion of TAVI (age 70), M-TEER (Class I ventricular SMR), and transcatheter TR (Class IIa) indications. MDT and BSX, both diversified, trade on company-specific issues. The CMS TAVR NCA reopening is a near-term catalyst that could expand the US TAVI envelope further; the durability debate at 10 years is the medium-term risk to all of them.
Clinical Trial Updates
Aortic — Adjunctive devices:
- NCT07276711 — CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material. Status: RECRUITING. Phase: NA. Enrollment: 663. Sponsor: EmStop Inc. Last updated 2026-06-26. Interventions: EmStop Embolic Protection System vs. Boston Scientific Sentinel. A head-to-head cerebral embolic protection trial — Sentinel has Class IIb support but inconsistent stroke-reduction signal across PROTECTED TAVR and meta-analyses; CAPTURE-2 is the next chance to settle the CEP question for TAVI.
No status changes today across the landmark pivotal portfolio (REPAIR-MR, PRIMARY, TRILUMINATE Pivotal, CLASP TR, TRISCEND II, EARLY TAVR, PARTNER follow-up, Evolut Low Risk follow-up).
Looking Ahead
Edwards earnings on July 23 will be the first public read on Evoque and PASCAL pull-through following the ESC 2025 transcatheter tricuspid IIa endorsement; the CMS TAVR NCA comment window remains the policy variable that could materially expand the US TAVI envelope before the next ACC/AHA guideline update. Watch both.
— E. Nolan Beckett, MD